<DOC>
	<DOCNO>NCT00463125</DOCNO>
	<brief_summary>- Systemic sclerosis ( scleroderma ; SSc ) connective tissue disease characterize progressive fibrosis skin visceral organ . - A diffuse cutaneous microvascular damage occur 30-50 % patient , often leading digital ulcer development , responsible pain , functional disability , disfigure scar , digital bony reabsorption , infection osteomyelitis . - Although availability drug i.v . prostacyclin analog , oral vasodilating agent , oral phosphodiesterase-5 inhibitor , oral endothelin receptor blocker improve prognosis , digital ulcer frequently refractory medical treatment . - Preliminary data seem demonstrate pivotal role play growth factor ( PDGF , TGF beta 1-2 , IGF ) process ulcer heal : tissue regeneration re-epithelization . Alpha-granules platelet store factor significant amount . - Recently , application gel rich platelet , prepared donor ’ plasma take apheresis , seem beneficial enhance pressure vascular ulcer heal . - On basis consideration expect application platelet gel , combine advance dress conventional medical therapy , make rapid heal digital ulcer patient systemic sclerosis . We decide conduct double blind RCT test hypothesis</brief_summary>
	<brief_title>Platelet Gel Systemic Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>Digital ulcer ( NPUAP stage≥2 ) patient SSc ( ACR criterion ) Current medical treatment intravenous prostanoids Availability come centre weekly ulcer assessment medication Capacity give inform consent Clinical evidence skin infection Current treatment Bosentan Sildenafil Presence necrotic material occlude wound bed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Scleroderma , systemic</keyword>
	<keyword>therapeutic</keyword>
	<keyword>platelet gel</keyword>
</DOC>